Integrated Quantitative Investments LLC Invests $912,000 in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Integrated Quantitative Investments LLC acquired a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 9,900 shares of the medical instruments supplier’s stock, valued at approximately $912,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LMAT. Raymond James Financial Inc. acquired a new position in LeMaitre Vascular during the fourth quarter worth about $14,900,000. Segall Bryant & Hamill LLC acquired a new stake in LeMaitre Vascular during the fourth quarter worth about $5,446,000. DF Dent & Co. Inc. raised its stake in LeMaitre Vascular by 26.2% during the third quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock worth $24,037,000 after purchasing an additional 53,797 shares during the period. JPMorgan Chase & Co. boosted its holdings in LeMaitre Vascular by 45.9% in the 4th quarter. JPMorgan Chase & Co. now owns 147,489 shares of the medical instruments supplier’s stock valued at $13,590,000 after purchasing an additional 46,430 shares during the last quarter. Finally, Barclays PLC boosted its holdings in LeMaitre Vascular by 394.5% in the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock valued at $3,396,000 after purchasing an additional 29,180 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on LMAT. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Wells Fargo & Company assumed coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price target on the stock. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Oppenheimer cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Finally, Lake Street Capital boosted their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, LeMaitre Vascular presently has an average rating of “Moderate Buy” and a consensus target price of $95.25.

LeMaitre Vascular Price Performance

NASDAQ:LMAT opened at $81.84 on Friday. The firm has a market capitalization of $1.85 billion, a PE ratio of 44.72, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. The business’s fifty day moving average price is $91.96 and its 200 day moving average price is $94.22. LeMaitre Vascular, Inc. has a 12 month low of $62.39 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $55.81 million during the quarter, compared to analysts’ expectations of $55.99 million. As a group, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend was Thursday, March 13th. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s payout ratio is 41.24%.

Insiders Place Their Bets

In related news, insider Trent G. Kamke sold 2,009 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now directly owns 5,564 shares of the company’s stock, valued at $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.79% of the stock is owned by insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.